The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 19, 2015
Filed:
Mar. 14, 2012
Applicants:
Tsuyoshi Busujima, Toshima-ku, JP;
Takahiro Oi, Toshima-ku, JP;
Hiroaki Tanaka, Toshima-ku, JP;
Yoshihisa Shirasaki, Toshima-ku, JP;
Kanako Iwakiri, Toshima-ku, JP;
Nagaaki Sato, Toshima-ku, JP;
Shigeru Tokita, Toshima-ku, JP;
Inventors:
Tsuyoshi Busujima, Toshima-ku, JP;
Takahiro Oi, Toshima-ku, JP;
Hiroaki Tanaka, Toshima-ku, JP;
Yoshihisa Shirasaki, Toshima-ku, JP;
Kanako Iwakiri, Toshima-ku, JP;
Nagaaki Sato, Toshima-ku, JP;
Shigeru Tokita, Toshima-ku, JP;
Assignee:
TAISHO PHARMACEUTICAL CO., LTD., Tokyo, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); C07D 209/44 (2006.01); C07D 217/04 (2006.01); C07D 223/16 (2006.01); C07D 405/12 (2006.01); C07D 409/06 (2006.01); C07D 413/06 (2006.01); C07D 417/10 (2006.01); A61K 31/4035 (2006.01); A61K 31/454 (2006.01); A61K 31/472 (2006.01); A61K 31/497 (2006.01); C07D 217/18 (2006.01); C07D 217/06 (2006.01); C07D 217/22 (2006.01); C07D 401/06 (2006.01); C07D 401/10 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/06 (2006.01); C07D 413/12 (2006.01); C07D 417/06 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); C07D 217/20 (2006.01); C07D 217/26 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 495/04 (2006.01); C07D 217/10 (2006.01); C07D 401/08 (2006.01);
U.S. Cl.
CPC ...
C07D 217/18 (2013.01); C07D 209/44 (2013.01); C07D 217/04 (2013.01); C07D 217/06 (2013.01); C07D 217/22 (2013.01); C07D 223/16 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/06 (2013.01); C07D 413/12 (2013.01); C07D 417/06 (2013.01); A61K 9/1623 (2013.01); A61K 9/2018 (2013.01); A61K 9/4858 (2013.01); C07D 217/20 (2013.01); C07D 217/26 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/06 (2013.01); C07D 409/14 (2013.01); C07D 413/06 (2013.01); C07D 417/10 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 495/04 (2013.01); C07D 401/14 (2013.01); C07D 217/10 (2013.01); C07D 401/08 (2013.01);
Abstract
There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein wherein